GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sihuan Pharmaceutical Holdings Group Ltd (OTCPK:SHPHF) » Definitions » Debt-to-EBITDA

Sihuan Pharmaceutical Holdings Group (Sihuan Pharmaceutical Holdings Group) Debt-to-EBITDA : 5.64 (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Sihuan Pharmaceutical Holdings Group Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sihuan Pharmaceutical Holdings Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $42.0 Mil. Sihuan Pharmaceutical Holdings Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $134.0 Mil. Sihuan Pharmaceutical Holdings Group's annualized EBITDA for the quarter that ended in Dec. 2023 was $31.2 Mil. Sihuan Pharmaceutical Holdings Group's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 5.64.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Sihuan Pharmaceutical Holdings Group's Debt-to-EBITDA or its related term are showing as below:

SHPHF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.84   Med: 0.05   Max: 3.76
Current: 3.76

During the past 13 years, the highest Debt-to-EBITDA Ratio of Sihuan Pharmaceutical Holdings Group was 3.76. The lowest was -0.84. And the median was 0.05.

SHPHF's Debt-to-EBITDA is ranked worse than
71.86% of 661 companies
in the Drug Manufacturers industry
Industry Median: 1.69 vs SHPHF: 3.76

Sihuan Pharmaceutical Holdings Group Debt-to-EBITDA Historical Data

The historical data trend for Sihuan Pharmaceutical Holdings Group's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sihuan Pharmaceutical Holdings Group Debt-to-EBITDA Chart

Sihuan Pharmaceutical Holdings Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 0.72 1.17 -0.84 3.76

Sihuan Pharmaceutical Holdings Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.26 1.76 -0.34 2.99 5.64

Competitive Comparison of Sihuan Pharmaceutical Holdings Group's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Sihuan Pharmaceutical Holdings Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sihuan Pharmaceutical Holdings Group's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sihuan Pharmaceutical Holdings Group's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sihuan Pharmaceutical Holdings Group's Debt-to-EBITDA falls into.



Sihuan Pharmaceutical Holdings Group Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sihuan Pharmaceutical Holdings Group's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(41.965 + 134.032) / 46.821
=3.76

Sihuan Pharmaceutical Holdings Group's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(41.965 + 134.032) / 31.23
=5.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Sihuan Pharmaceutical Holdings Group  (OTCPK:SHPHF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Sihuan Pharmaceutical Holdings Group Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sihuan Pharmaceutical Holdings Group's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Sihuan Pharmaceutical Holdings Group (Sihuan Pharmaceutical Holdings Group) Business Description

Traded in Other Exchanges
Address
Zhubang 2000 Business Centre, 22nd Floor, Building 4, West Balizhuang, Chaoyang District, Beijing, CHN, 100025
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Digestive System, Anti-Infective, metabolism, Respiratory, Neurology, and Others. The group has three reportable segments: the medical aesthetic products segment including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others to provide non- or minimally invasive medical aesthetics comprehensive solutions; the innovative medicine and other medicine segments; and the generic medicine segment.